| 
		Vietnam develops 'world's first' African swine fever vaccine for 
		commercial use
		 Send a link to a friend 
		
		 [June 01, 2022] 
		HANOI (Reuters) - Vietnam said on 
		Wednesday it had successfully developed a vaccine to administer to pigs 
		to fight African swine fever, with the aim of becoming the first country 
		to commercially produce and export it. 
 African swine fever, one of the most devastating livestock diseases, was 
		first detected in Vietnam in February 2019 and forced the country to 
		cull around 20% of its hog herd last year.
 
 It originated in Africa before spreading to Europe and Asia and has 
		killed hundreds of millions of pigs globally. African swine fever is 
		harmless to humans.
 
 
		
		 
		"This is a milestone of the veterinary industry," deputy agriculture 
		minister Phung Duc Tien said in a statement.
 
 "With immunity lasting six months, the vaccine will be a shield for 
		hog-raising industry and pig production globally."
 
 The vaccine has been in development since November 2019 in partnership 
		with United States experts, with five clinical trials held.
 
		[to top of second column] | 
            
			 
            
			Pigs are seen at a farm outside Hanoi, Vietnam June 28, 2019. 
			Picture taken June 28, 2019. REUTERS/Kham 
            
			
			
			 Its safety and efficacy was 
			confirmed by the Agricultural Research Service under the U.S. 
			Department of Agriculture, Tien said.  "This success opens great expectations and the room 
			to export African swine fever vaccine produced in Vietnam is huge," 
			Tien added. 
 He did not provide a timeframe for when the vaccine could be 
			exported or estimate of Vietnam's production capacity.
 
 Although the swine fever outbreak has subsided in Vietnam, allowing 
			farmers to rebuild hog herds, the virus is still hurting farms in 
			some countries.
 
 (Reporting by Phuong Nguyen; Editing by Martin Petty)
 
			[© 2022 Thomson Reuters. All rights 
				reserved.]  This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. 
			
			 |